Progress in Using Designed Nanoparticles to Treat Lung Diseases: Current Understanding and Future Directions

Engineered nanoparticles (ENPs) have shown promise in overcoming limitations of traditional treatments for respiratory diseases.

• Conventional therapies for respiratory diseases often have poor effectiveness due to issues like low bioavailability and inadequate penetration of lung barriers.
• ENPs can encapsulate therapeutic agents, allowing for targeted delivery and controlled release, which may reduce systemic toxicity.
• Inhalable ENPs designed to target lung cancer cell receptors are capable of penetrating lung barriers and delivering drugs effectively within lung tissue.
• Recent advances in nanotechnology have expanded the potential uses of ENPs in gene therapy, immune modulation, and pulmonary tissue repair.
• Challenges remain in the clinical translation of ENPs, including nanoparticle variability, inhalation difficulties, and issues with reproducibility and scalability.

Simplified